Schiavi & Co’s AbbVie ABBV Stock Holding History

Schiavi & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$786K	Buy	3,125 +14	+0.5%	+$3.01K	0.21%	19
2026 Q1	$677K	Buy	3,111 +10	+0.3%	+$2.22K	0.2%	20
2025 Q4	$708K	Hold	3,101	–	–	0.23%	18
2025 Q3	$718K	Sell	3,101 -92	-3%	-$18.7K	0.24%	15
2025 Q2	$593K	Hold	3,193	–	–	0.2%	16
2025 Q1	$669K	Sell	3,193 -353	-10%	-$68.6K	0.25%	13
2024 Q4	$630K	Hold	3,546	–	–	0.25%	12
2024 Q3	$700K	Buy	3,546 +225	+7%	+$42K	0.25%	12
2024 Q2	$570K	Buy	3,321 +249	+8%	+$41.2K	0.22%	14
2024 Q1	$559K	Sell	3,072 -850	-22%	-$146K	0.22%	14
2023 Q4	$608K	Sell	3,922 -106	-3%	-$15.5K	0.25%	14
2023 Q3	$600K	Buy	+4,028	New	+$591K	0.25%	13

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Schiavi & Co's ABBV Position: Q2 2026 in Review

Schiavi & Co increased its AbbVie (ABBV) stake by 0.45% in Q2 2026, buying an estimated $3.01K and bringing the position to 3,125 shares worth $786K. The position accounts for 0.21% of the portfolio, ranked #19.

Schiavi & Co first reported a position in ABBV in Q3 2023 and has held it in 12 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Schiavi & Co held 3,125 shares of AbbVie worth $786K as of Q2 2026.
Schiavi & Co bought 14 AbbVie shares in Q2 2026, an estimated $3.01K.
AbbVie made up 0.21% of Schiavi & Co's portfolio in Q2 2026, its #19 holding.
Schiavi & Co first reported a position in AbbVie in Q3 2023 and has held it in 12 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Schiavi & Co's 13F filing for Q2 2026, filed 10 Aug 2026.